AstraZeneca announced that the company has submitted applications in the European Union (EU) for once-daily SEROQUEL XR™ (quetiapine fumarate) Extended-Release Tablets (quetiapine XR), seeking approval for the treatment of major depressive disorder (MDD) including maintenance therapy in adult patients using Mutual Recognition Procedure (MRP). This follows an sNDA submission for SEROQUEL XR in MDD in the U.S. in February this year.
Popularity: unranked [?]
Related posts:
- Astrazeneca Submits Seroquel XR For The Treatment Of Bipolar Mania And Bipolar Depression, And Seroquel(R) For The Treatment Of Bipolar Depression
- US FDA Approves SEROQUEL XR(R) For Add-On Treatment Of Major Depressive Disorder
- US FDA Approves SEROQUEL XR(R) For Add-On Treatment Of Major Depressive Disorder
- New Data Presented For SEROQUEL XRTM In Major Depressive Disorder And Generalised Anxiety Disorder
- Valdoxan(R) Granted Marketing Authorisation For The Treatment Of Major Depressive Episodes In Europe
Comments
No Responses to “Astrazeneca Submits Seroquel XR™ In Europe For The Treatment Of Major Depressive Disorder”